Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
7.81
-0.49 (-5.90%)
Dec 18, 2025, 4:00 PM EST - Market closed
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 30.00K CHF in the quarter ending September 30, 2025, a decrease of -44.28%. This brings the company's revenue in the last twelve months to 31.51K, down -94.33% year-over-year. In the year 2024, Addex Therapeutics had annual revenue of 404.10K, down -74.95%.
Revenue (ttm)
31.51K CHF
Revenue Growth
-94.33%
P/S Ratio
41.23
Revenue / Employee
15,754 CHF
Employees
2
Market Cap
8.20M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 404.10K | -1.21M | -74.95% |
| Dec 31, 2023 | 1.61M | 190.52K | 13.39% |
| Dec 31, 2022 | 1.42M | -1.49M | -51.22% |
| Dec 31, 2021 | 2.92M | -696.51K | -19.28% |
| Dec 31, 2020 | 3.61M | 849.99K | 30.77% |
| Dec 31, 2019 | 2.76M | -3.28M | -54.29% |
| Dec 31, 2018 | 6.04M | 5.54M | 1,109.03% |
| Dec 31, 2017 | 499.89K | 214.80K | 75.35% |
| Dec 31, 2016 | 285.09K | -30.61K | -9.70% |
| Dec 31, 2015 | 315.70K | 7.92K | 2.57% |
| Dec 31, 2014 | 307.78K | 165.69K | 116.61% |
| Dec 31, 2013 | 142.09K | 21.00K | 17.34% |
| Dec 31, 2012 | 121.09K | -2.70M | -95.71% |
| Dec 31, 2011 | 2.82M | 848.18K | 42.94% |
| Dec 31, 2010 | 1.98M | -2.12M | -51.71% |
| Dec 31, 2009 | 4.09M | -22.72M | -84.74% |
| Dec 31, 2008 | 26.81M | 26.32M | 5,405.31% |
| Dec 31, 2007 | 486.93K | -4.25M | -89.73% |
| Dec 31, 2006 | 4.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADXN News
- 8 days ago - Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. - GlobeNewsWire
- 14 days ago - Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 18 days ago - Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 - GlobeNewsWire
- 2 months ago - Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 - GlobeNewsWire
- 3 months ago - Addex Appoints Bank of New York Mellon as Depositary Bank - GlobeNewsWire